HA
ALXO icon

HC Advisors’s ALX Oncology ALXO Stock Holding History

HC Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.9K Sell
22,900
-1,000
-4% -$1.91K 0.03% 59
2025
Q4 		$27K Buy
23,900
+2,050
+9% +$3.1K 0.02% 59
2025
Q3 		$40K Buy
21,850
+1,350
+7% +$1.17K 0.03% 60
2025
Q2 		$8.51K Sell
20,500
-1,000
-5% -$505 0.01% 59
2025
Q1 		$13.4K Buy
21,500
+6,025
+39% +$7.23K 0.01% 61
2024
Q4 		$25.8K Sell
15,475
-300
-2% -$461 0.02% 58
2024
Q3 		$28.7K Buy
+15,775
New +$58.6K 0.02% 52
2022
Q4 		– Sell
-13,933
Closed -$133K – 87
2022
Q3 		$133K Sell
13,933
-190
-1% -$2.21K 0.09% 80
2022
Q2 		$114K Buy
14,123
+333
+2% +$3.63K 0.08% 76
2022
Q1 		$233K Sell
13,790
-4,202
-23% -$71.7K 0.15% 77
2021
Q4 		$387K Buy
17,992
+9,786
+119% +$422K 0.24% 53
2021
Q3 		$606K Sell
8,206
-572
-7% -$38.1K 0.4% 38
2021
Q2 		$480K Sell
8,778
-167
-2% -$9.99K 0.3% 46
2021
Q1 		$660K Sell
8,945
-858
-9% -$67.5K 0.43% 37
2020
Q4 		$845K Buy
9,803
+3,300
+51% +$199K 0.58% 30
2020
Q3 		$245K Buy
+6,503
New +$256K 0.2% 58

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

HC Advisors's ALXO Position: Q1 2026 in Review

HC Advisors reduced its ALX Oncology (ALXO) stake by 4.2% in Q1 2026, selling an estimated $1.91K and leaving 22,900 shares worth $45.9K. The position accounts for 0.03% of the portfolio, ranked #59.

HC Advisors first reported a position in ALXO in Q3 2020 and has held it in 16 quarters since. The position peaked at $845K in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • HC Advisors held 22,900 shares of ALX Oncology worth $45.9K as of Q1 2026.
  • HC Advisors sold 1,000 ALX Oncology shares in Q1 2026, an estimated $1.91K.
  • ALX Oncology made up 0.03% of HC Advisors's portfolio in Q1 2026, its #59 holding.
  • HC Advisors first reported a position in ALX Oncology in Q3 2020 and has held it in 16 quarters since.
  • HC Advisors's ALX Oncology position peaked at $845K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on HC Advisors's 13F filing for Q1 2026, filed 5 May 2026.